Last updated: 2026-09-13 05:01:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
CollPlant Biotechnologies Ltd (CLGN) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $3,49, with a market capitalization of $6,69M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2,64 to $31,80. This page covers its latest market performance, valuation, price trends and company information.
$6,69M | |
$3,56 | |
$242,60 | |
$2,64 | |
$3,54 | |
126,31K | |
341,69K | |
-- | |
$31,80 | |
$2,64 | |
-- | |
-- |
CollPlant Biotechnologies Ltd (CLGN) last closed at $3,54 as of 2026-09-11 23:52:00, unchanged from the previous close of $3,54.
During the latest regular trading session, CLGN traded between $2,64 and $242,60, with a volume of 126,31K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, CollPlant Biotechnologies Ltd (CLGN) moved from $3,43 to $3,49, representing a gain of 1,78% ($0,06).
The stock traded between $2,91 and $3,91 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 183,58 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 2,9%
CLGN is currently trading at $3,49, placing it 2,9% of the way from its 52-week low of $2,64 to its 52-week high of $31,80. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
| Employees | 39 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of CollPlant Biotechnologies Ltd (CLGN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.